<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205699</url>
  </required_header>
  <id_info>
    <org_study_id>NIMH</org_study_id>
    <secondary_id>R01MH072912</secondary_id>
    <nct_id>NCT00205699</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Antipsychotics in Children</brief_title>
  <acronym>MEAC</acronym>
  <official_title>Metabolic Effects of Antipsychotics in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project aims to describe and compare the outcome of 12 weeks of prospective, randomized
      treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle,
      liver and adipose tissue, abdominal fat mass, total body and fat-free mass, efficacy for
      symptoms of aggression and non-metabolic adverse events. Children aged 6-18 will be studied,
      exploring effects of stimulant therapy and age-related differences in vulnerability to
      treatment-induced adverse metabolic changes. Aims are addressed by measuring glucose and
      lipid kinetics with stable isotope tracers, body composition with dual energy x-ray
      absorptiometry and magnetic resonance imaging (MRI), and standardized assessments of efficacy
      and adverse events. Relevant data are critically needed to target clinical therapy and basic
      research, identify medical risks, and guide regulatory decisions in this vulnerable
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized clinical trial assesses both the safety and efficacy of atypical
      antipsychotic agents in antipsychotic-naive aggressive children with various childhood
      psychiatric disorders during 12 weeks of prospective, randomized treatment with olanzapine,
      risperidone or aripiprazole.

      Aim 1: To evaluate effects of selected antipsychotic treatments on insulin action in muscle
      (glucose disposal), liver (glucose production) and adipose tissue (lipolysis).

      Aim 2: To evaluate effects of selected antipsychotic treatments on abdominal fat mass, total
      body fat and total fat-free mass.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DEXA % Body Fat</measure>
    <time_frame>12 weeks</time_frame>
    <description>This study hypothesized that antipsychotic treatment would increase percent total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)</measure>
    <time_frame>12 weeks</time_frame>
    <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at muscle, as measured by the insulin-stimulated rate of disappearance of glucose (glucose Rd), with larger adverse effects for olanzapine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)</measure>
    <time_frame>12 weeks</time_frame>
    <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at adipose tissue, as measured by the insulin-stimulated rate of disappearance of glycerol (glycerol Ra), with larger adverse effects for olanzapine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)</measure>
    <time_frame>12 weeks</time_frame>
    <description>This study hypothesized that antipsychotic treatment would decrease hepatic insulin sensitivity, as measured by the rate of appearance of glucose (glucose Ra), with larger adverse effects for olanzapine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MRI-measured Visceral Abdominal Fat</measure>
    <time_frame>12 weeks</time_frame>
    <description>This study hypothesized that antipsychotic treatment would increase visceral abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MRI-measured Subcutaneous Abdominal Fat</measure>
    <time_frame>12 weeks</time_frame>
    <description>This study hypothesized that antipsychotic treatment would increase subcutaneous abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Aggression</condition>
  <condition>Attention Deficit-Hyperactivity</condition>
  <condition>Oppositional Defiant Disorder</condition>
  <condition>Pervasive Development Disorders</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will be randomized to flexibly-dosed treatment with risperidone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>randomized to begin 12 week trial of risperidone</description>
    <arm_group_label>risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>randomized to begin 12 week trial of olanzapine</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <description>randomized to 12 week trial of aripiprazole</description>
    <arm_group_label>aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 6-18 years

          -  Generally healthy and a score of ≥ 18 on the Aberrant Behavior Checklist in the
             context of one or more Axis I Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition (DSM-IV) childhood psychiatric disorders, including conduct disorder,
             oppositional defiant disorder, disruptive behavior disorder, autism, pervasive
             developmental disorder, attention deficit disorder, schizophrenia and bipolar
             affective disorders

          -  Children's Global Assessment Scale (CGAS) score ≤ 60

          -  Not previously treated with an antipsychotic; individual subjects with remote, brief
             prior antipsychotic exposure may be considered for enrollment by the PI on a case by
             case basis

          -  Patient assent and informed consent obtained from the parent or guardian

          -  No clinically significant (based on PI determination) changes in permitted medications
             (e.g., stimulants and selective serotonin reuptake inhibitors [SSRIs]) for
             approximately 1 month prior to Baseline evaluations

        Exclusion Criteria:

          -  Active suicidality or primary dx of major depressive disorder

          -  Any lifetime use of antipsychotics or non-serotonin selective reuptake inhibitor
             (non-SSRI) anti-depressants

          -  The presence of any serious medical disorder, based on PI determination, that may
             confound the assessment of relevant biologic measures or diagnoses, including:

               -  significant organ system dysfunction;

               -  endocrine disease, including type 1 or type 2 diabetes mellitus;

               -  coagulopathy;

               -  anemia;

               -  or acute infection.

          -  Subjects regularly taking any glucose lowering agent, lipid lowering agent, exogenous
             testosterone, recombinant human growth hormone, or any other endocrine agent that
             might confound substrate metabolism, oral glucocorticoids (glucocorticoid inhalants
             and nasal sprays are permitted), antihistamines, sedating antihistamines (non-sedating
             antihistamines such as but not limited to Claritin (loratadine) and Zyrtec
             (cetirizine) are permitted), and certain mood stabilizing agents, as some medications
             may themselves worsen or otherwise alter weight gain, glucose and lipid regulation or
             otherwise make it difficult to assess the effects of the antipsychotic alone; (note
             that exposure to many psychotropic agents including stimulants and SSRI's is permitted
             in order to maintain the generalizability of the sample);

          -  Intelligence quotient (IQ) &lt; 70 (based on school records and/or evaluation by
             clinician)

          -  current substance abuse

          -  Past history or currently has dyskinesia

          -  Stimulant dosage significantly higher (per PI judgment)than the equivalent of
             approximately 2mg/kg/day methylphenidate equivalent dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W. Newcomer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Atlantic University and Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ginger Nicol, MD</last_name>
    <role>Study Director</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine, Psychiatry Dept.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>June 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2018</results_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antipsychotic treatment</keyword>
  <keyword>Insulin action/secretion</keyword>
  <keyword>Abdominal fat mass, total body fat</keyword>
  <keyword>Aggression</keyword>
  <keyword>Resting metabolic rates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Attention Deficit and Disruptive Behavior Disorders</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form: Child and Adult Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 18, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Genetics Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 30, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Post-enrollment screening for inclusion and exclusion criteria, e.g. for exclusionary conditions like diabetes mellitus.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Risperidone</title>
          <description>12 weeks of randomized treatment with flexibly dosed risperidone</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine</title>
          <description>12 weeks of randomized treatment with flexibly dosed olanzapine</description>
        </group>
        <group group_id="P3">
          <title>Aripiprazole</title>
          <description>12 weeks of randomized treatment with flexibly dosed aripiprazole</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risperidone</title>
          <description>12 weeks randomized, flexibly-dosed treatment with risperidone</description>
        </group>
        <group group_id="B2">
          <title>Olanzapine</title>
          <description>12 weeks randomized, flexibly-dosed treatment with olanzapine</description>
        </group>
        <group group_id="B3">
          <title>Aripiprazole</title>
          <description>12 weeks randomized, flexibly-dosed treatment with aripiprazole</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.32" spread="2.95"/>
                    <measurement group_id="B2" value="11.10" spread="2.52"/>
                    <measurement group_id="B3" value="11.60" spread="2.92"/>
                    <measurement group_id="B4" value="11.35" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Attention Deficit Hyperactivity Disorder</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disruptive Behavior Disorder</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood Disorder</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autism Spectrum Disorder</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obsessive Compulsive Disorder</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tourette Disorder</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Improvement (CGI)-Severity of Illness</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderately ill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Markedly ill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely ill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavioral Checklist Subscales</title>
          <description>This instrument is a five-factor scale comprising 58 items in 5 sub scales. Items are scored on a scale of 0 (not a problem) to 3 (severe problem). Each sub scale score is the sum of items in the scale. The overall score is the sum of all items. Sub scales are Irritability (15 items, 0-45, clinical significance &gt;18); Lethargy (16 items, min 0, max 48, clinical significance &gt;9); Stereotypic Behavior; (7 items, 0 - 21, clinical significance &gt;3) Hyperactivity, Noncompliance (16 items, 0-48, clinical significance &gt;24); and Inappropriate Speech (4 items, 0-12, clinical significance &gt;3).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.03" spread="23.96"/>
                    <measurement group_id="B2" value="81.89" spread="21.55"/>
                    <measurement group_id="B3" value="83.53" spread="25.70"/>
                    <measurement group_id="B4" value="84.54" spread="23.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/Aggression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.49" spread="5.53"/>
                    <measurement group_id="B2" value="28.17" spread="5.73"/>
                    <measurement group_id="B3" value="28.14" spread="6.27"/>
                    <measurement group_id="B4" value="28.27" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lethargy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.57" spread="10.01"/>
                    <measurement group_id="B2" value="12.67" spread="8.15"/>
                    <measurement group_id="B3" value="14.61" spread="8.83"/>
                    <measurement group_id="B4" value="14.66" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stereotypy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.54" spread="4.95"/>
                    <measurement group_id="B2" value="5.15" spread="4.42"/>
                    <measurement group_id="B3" value="4.29" spread="4.61"/>
                    <measurement group_id="B4" value="4.99" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.83" spread="9.68"/>
                    <measurement group_id="B2" value="32.11" spread="10.45"/>
                    <measurement group_id="B3" value="32.80" spread="10.88"/>
                    <measurement group_id="B4" value="32.59" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inappropriate Speech</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.60" spread="3.02"/>
                    <measurement group_id="B2" value="3.78" spread="2.71"/>
                    <measurement group_id="B3" value="3.69" spread="2.76"/>
                    <measurement group_id="B4" value="4.03" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Assessment of Functioning</title>
          <description>This instrument is a global measure of severity based on psychiatric symptomatology and impairment of adaptation in family, social, school, and work areas. On this scale 0 is worst, 100 is best, and ≤ 60 is definite clinical impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.71" spread="4.44"/>
                    <measurement group_id="B2" value="50.67" spread="5.44"/>
                    <measurement group_id="B3" value="50.88" spread="6.00"/>
                    <measurement group_id="B4" value="51.10" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Suspensions</title>
          <population>Measure Analysis Population Description: The n's reported here represent complete data only.</population>
          <units>number of discrete school suspensions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="46"/>
                    <count group_id="B4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.60" spread="4.11"/>
                    <measurement group_id="B2" value="2.71" spread="3.98"/>
                    <measurement group_id="B3" value="2.85" spread="4.18"/>
                    <measurement group_id="B4" value="2.72" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On stimulant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On Selective Serotonin Reuptake Inhibitors (SSRI)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DEXA-measured body composition (%)</title>
          <units>percentage of body composition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>DEXA Total % Fat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.25" spread="10.64"/>
                    <measurement group_id="B2" value="24.48" spread="10.19"/>
                    <measurement group_id="B3" value="26.23" spread="10.83"/>
                    <measurement group_id="B4" value="25.68" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEXA Total % Lean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.30" spread="10.35"/>
                    <measurement group_id="B2" value="71.96" spread="9.96"/>
                    <measurement group_id="B3" value="70.32" spread="10.53"/>
                    <measurement group_id="B4" value="70.84" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DEXA-measured body composition (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>DEXA Total Fat kg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.50" spread="9.53"/>
                    <measurement group_id="B2" value="10.46" spread="6.68"/>
                    <measurement group_id="B3" value="13.24" spread="10.40"/>
                    <measurement group_id="B4" value="12.10" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEXA Total Lean kg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.38" spread="11.01"/>
                    <measurement group_id="B2" value="29.30" spread="9.83"/>
                    <measurement group_id="B3" value="31.98" spread="14.69"/>
                    <measurement group_id="B4" value="30.58" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Insulin Stimulated % Change in Isotopomer Measurement during Week 0 Clamp</title>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: The n's reported here represent complete data only.</population>
          <units>% change during baseline clamp</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>% Change in Glucose Rate of Disappearance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.26" spread="78.79"/>
                    <measurement group_id="B2" value="168.75" spread="82.09"/>
                    <measurement group_id="B3" value="156.49" spread="81.14"/>
                    <measurement group_id="B4" value="163.56" spread="80.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change in Glucose Rate of Appearance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.19" spread="10.94"/>
                    <measurement group_id="B2" value="82.53" spread="9.90"/>
                    <measurement group_id="B3" value="82.70" spread="12.15"/>
                    <measurement group_id="B4" value="82.83" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change in Glycerol Rate of Appearance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.59" spread="13.42"/>
                    <measurement group_id="B2" value="55.94" spread="15.08"/>
                    <measurement group_id="B3" value="50.46" spread="15.04"/>
                    <measurement group_id="B4" value="53.89" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Body Sensitivity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.96" spread="5.33"/>
                    <measurement group_id="B2" value="12.53" spread="4.47"/>
                    <measurement group_id="B3" value="12.87" spread="6.36"/>
                    <measurement group_id="B4" value="12.80" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MRI-measured abdominal fat</title>
          <population>The n's reported here represent complete data only.</population>
          <units>cm squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>MRI Subcutaneous Fat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="33"/>
                    <count group_id="B4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.38" spread="123.05"/>
                    <measurement group_id="B2" value="86.17" spread="65.10"/>
                    <measurement group_id="B3" value="111.16" spread="94.16"/>
                    <measurement group_id="B4" value="107.23" spread="98.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Visceral Fat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="33"/>
                    <count group_id="B4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.79" spread="18.45"/>
                    <measurement group_id="B2" value="19.37" spread="19.74"/>
                    <measurement group_id="B3" value="26.70" spread="24.14"/>
                    <measurement group_id="B4" value="24.11" spread="20.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Total Fat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="33"/>
                    <count group_id="B4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.17" spread="137.36"/>
                    <measurement group_id="B2" value="106.09" spread="82.28"/>
                    <measurement group_id="B3" value="137.85" spread="116.24"/>
                    <measurement group_id="B4" value="131.56" spread="115.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.49" spread="19.08"/>
                    <measurement group_id="B2" value="42.23" spread="13.81"/>
                    <measurement group_id="B3" value="47.94" spread="23.57"/>
                    <measurement group_id="B4" value="45.28" spread="19.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.72" spread="13.47"/>
                    <measurement group_id="B2" value="65.87" spread="11.03"/>
                    <measurement group_id="B3" value="69.54" spread="15.50"/>
                    <measurement group_id="B4" value="68.09" spread="13.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index Percentile</title>
          <units>percentile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.13" spread="29.70"/>
                    <measurement group_id="B2" value="58.38" spread="31.33"/>
                    <measurement group_id="B3" value="63.05" spread="30.12"/>
                    <measurement group_id="B4" value="61.25" spread="30.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass index z-score</title>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.49" spread="1.12"/>
                    <measurement group_id="B2" value="0.30" spread="1.11"/>
                    <measurement group_id="B3" value="0.55" spread="1.13"/>
                    <measurement group_id="B4" value="0.45" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting laboratory values (mg/dL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Fasting Glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.14" spread="8.81"/>
                    <measurement group_id="B2" value="87.48" spread="6.55"/>
                    <measurement group_id="B3" value="88.98" spread="6.16"/>
                    <measurement group_id="B4" value="88.56" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144.74" spread="28.88"/>
                    <measurement group_id="B2" value="137.09" spread="25.31"/>
                    <measurement group_id="B3" value="135.45" spread="28.34"/>
                    <measurement group_id="B4" value="139.14" spread="27.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.40" spread="33.00"/>
                    <measurement group_id="B2" value="60.98" spread="31.89"/>
                    <measurement group_id="B3" value="52.16" spread="23.13"/>
                    <measurement group_id="B4" value="57.78" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.53" spread="25.41"/>
                    <measurement group_id="B2" value="72.00" spread="24.56"/>
                    <measurement group_id="B3" value="72.82" spread="26.00"/>
                    <measurement group_id="B4" value="74.84" spread="25.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.37" spread="0.25"/>
                    <measurement group_id="B2" value="0.40" spread="0.18"/>
                    <measurement group_id="B3" value="0.33" spread="0.18"/>
                    <measurement group_id="B4" value="0.37" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Fasting Laboratory Values (IU/L)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Alanine aminotransferase (ALT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.10" spread="7.74"/>
                    <measurement group_id="B2" value="13.83" spread="4.20"/>
                    <measurement group_id="B3" value="15.53" spread="4.49"/>
                    <measurement group_id="B4" value="15.86" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminostransferase (AST)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.65" spread="7.10"/>
                    <measurement group_id="B2" value="23.26" spread="6.12"/>
                    <measurement group_id="B3" value="23.94" spread="6.78"/>
                    <measurement group_id="B4" value="24.31" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209.33" spread="88.42"/>
                    <measurement group_id="B2" value="222.54" spread="75.69"/>
                    <measurement group_id="B3" value="206.41" spread="85.35"/>
                    <measurement group_id="B4" value="212.56" spread="83.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting laboratory values (g/dL)</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Albumin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.02" spread="0.25"/>
                    <measurement group_id="B2" value="4.06" spread="0.27"/>
                    <measurement group_id="B3" value="4.05" spread="0.25"/>
                    <measurement group_id="B4" value="4.05" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.95" spread="0.46"/>
                    <measurement group_id="B2" value="6.90" spread="0.39"/>
                    <measurement group_id="B3" value="6.95" spread="0.34"/>
                    <measurement group_id="B4" value="6.94" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Sensitivity c-Reactive Protein (HS-CRP)</title>
          <population>The n's reported here represent complete data only.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.61" spread="3.04"/>
                    <measurement group_id="B2" value="1.37" spread="3.04"/>
                    <measurement group_id="B3" value="1.12" spread="1.53"/>
                    <measurement group_id="B4" value="1.37" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Insulin</title>
          <population>The n's reported here represent complete data only.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.64" spread="5.85"/>
                    <measurement group_id="B2" value="6.24" spread="3.74"/>
                    <measurement group_id="B3" value="9.00" spread="8.68"/>
                    <measurement group_id="B4" value="7.65" spread="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.46" spread="0.26"/>
                    <measurement group_id="B2" value="5.54" spread="0.34"/>
                    <measurement group_id="B3" value="5.54" spread="0.28"/>
                    <measurement group_id="B4" value="5.52" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in DEXA % Body Fat</title>
        <description>This study hypothesized that antipsychotic treatment would increase percent total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine.</description>
        <time_frame>12 weeks</time_frame>
        <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>12 weeks randomized, flexibly-dosed treatment with risperidone</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>12 weeks randomized, flexibly-dosed treatment with olanzapine</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole</title>
            <description>12 weeks randomized, flexibly-dosed treatment with aripiprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DEXA % Body Fat</title>
          <description>This study hypothesized that antipsychotic treatment would increase percent total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine.</description>
          <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
          <units>percent body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="3.11"/>
                    <measurement group_id="O2" value="4.12" spread="3.10"/>
                    <measurement group_id="O3" value="1.66" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Primary analysis for change in DEXA % fat used a likelihood-based mixed-effects model using time (0, 6 and 12 weeks) and medication group as independent variables, with Toeplitz covariance structure specified, based on Bayesian information criteria (BIC). The null hypotheses were that there was no difference in the outcome over time (main effect of time) and that there were no differences between groups in the change over time (time by treatment condition).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value refers to the time by treatment condition interaction. The a priori threshold for statistical significance in this planned primary test was p&lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)</title>
        <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at muscle, as measured by the insulin-stimulated rate of disappearance of glucose (glucose Rd), with larger adverse effects for olanzapine.</description>
        <time_frame>12 weeks</time_frame>
        <population>Children ages 6-18 with a Diagnostic and Statistical Manual Text Revision (DSM-IV-TR) diagnosis and clinically significant aggression or irritability</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>12 weeks randomized, flexibly-dosed treatment with risperidone</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>12 weeks randomized, flexibly-dosed treatment with olanzapine</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole</title>
            <description>12 weeks randomized, flexibly-dosed treatment with aripiprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)</title>
          <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at muscle, as measured by the insulin-stimulated rate of disappearance of glucose (glucose Rd), with larger adverse effects for olanzapine.</description>
          <population>Children ages 6-18 with a Diagnostic and Statistical Manual Text Revision (DSM-IV-TR) diagnosis and clinically significant aggression or irritability</population>
          <units>percentage of % change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="83.91"/>
                    <measurement group_id="O2" value="-29.34" spread="85.56"/>
                    <measurement group_id="O3" value="-30.26" spread="65.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)</title>
        <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at adipose tissue, as measured by the insulin-stimulated rate of disappearance of glycerol (glycerol Ra), with larger adverse effects for olanzapine.</description>
        <time_frame>12 weeks</time_frame>
        <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>12 weeks of randomized treatment with flexibly dosed risperidone</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>12 weeks of randomized treatment with flexibly dosed olanzapine</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole</title>
            <description>12 weeks of randomized treatment with flexibly dosed aripiprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)</title>
          <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at adipose tissue, as measured by the insulin-stimulated rate of disappearance of glycerol (glycerol Ra), with larger adverse effects for olanzapine.</description>
          <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
          <units>percentage of % change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.65" spread="17.23"/>
                    <measurement group_id="O2" value="-8.29" spread="22.39"/>
                    <measurement group_id="O3" value="1.70" spread="16.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)</title>
        <description>This study hypothesized that antipsychotic treatment would decrease hepatic insulin sensitivity, as measured by the rate of appearance of glucose (glucose Ra), with larger adverse effects for olanzapine.</description>
        <time_frame>12 weeks</time_frame>
        <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>12 weeks of randomized treatment with flexibly dosed risperidone</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>12 weeks of randomized treatment with flexibly dosed olanzapine</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole</title>
            <description>12 weeks of randomized treatment with flexibly dosed aripiprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)</title>
          <description>This study hypothesized that antipsychotic treatment would decrease hepatic insulin sensitivity, as measured by the rate of appearance of glucose (glucose Ra), with larger adverse effects for olanzapine.</description>
          <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
          <units>percentage of % change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="7.61"/>
                    <measurement group_id="O2" value="-6.57" spread="13.16"/>
                    <measurement group_id="O3" value="-3.27" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MRI-measured Visceral Abdominal Fat</title>
        <description>This study hypothesized that antipsychotic treatment would increase visceral abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine.</description>
        <time_frame>12 weeks</time_frame>
        <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>12 weeks of randomized treatment with flexibly dosed risperidone</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>12 weeks of randomized treatment with flexibly dosed olanzapine</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole</title>
            <description>12 weeks of randomized treatment with flexibly dosed aripiprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MRI-measured Visceral Abdominal Fat</title>
          <description>This study hypothesized that antipsychotic treatment would increase visceral abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine.</description>
          <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
          <units>Change in cm-squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="10.99"/>
                    <measurement group_id="O2" value="10.73" spread="14.50"/>
                    <measurement group_id="O3" value="12.04" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MRI-measured Subcutaneous Abdominal Fat</title>
        <description>This study hypothesized that antipsychotic treatment would increase subcutaneous abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine.</description>
        <time_frame>12 weeks</time_frame>
        <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>12 weeks of randomized treatment with flexibly dosed risperidone</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>12 weeks of randomized treatment with flexibly dosed olanzapine</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole</title>
            <description>12 weeks of randomized treatment with flexibly dosed aripiprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MRI-measured Subcutaneous Abdominal Fat</title>
          <description>This study hypothesized that antipsychotic treatment would increase subcutaneous abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine.</description>
          <population>Modified Intent to Treat (ITT) sample with week 0 and week 12 data.</population>
          <units>Change in cm-squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.21" spread="22.27"/>
                    <measurement group_id="O2" value="34.27" spread="27.22"/>
                    <measurement group_id="O3" value="15.84" spread="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA was used to test for the main effect of time on the outcome, and to test for a time by treatment condition interaction that would indicate differences between groups in change over time in the primary outcome. The null hypotheses were that there was no difference in the outcome over time (main effect of time) and that there were no differences between groups in the change over time (time by treatment condition).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.003</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Bonferroni correction for multiple comparisons was applied (p&lt;0.05/4 = 0.0125).</p_value_desc>
            <method>Contrast</method>
            <method_desc>Contrasts based on the ANCOVA-derived time by treatment condition interaction.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Bonferroni correction for multiple comparisons was applied (p&lt;0.05/4 = 0.0125).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Contrasts based on the ANCOVA-derived time by treatment condition interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the entire course of the study, April 2006 to July 2011 or 6 years and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>Participants in this group were randomized to treatment with aripiprazole.</description>
        </group>
        <group group_id="E2">
          <title>Olanzapine</title>
          <description>Participants in this group were randomized to treatment with olanzapine.</description>
        </group>
        <group group_id="E3">
          <title>Risperidone</title>
          <description>Participants in this group were randomized to treatment with risperidone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>About 2 months after starting Risperidone, participant had a complex partial seizure, later determined by a neurologist to be unrelated to study medication. Participant was restarted on the Risperidone.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental Injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Difficulty Concentrating</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Drowsiness/Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Involuntary Movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Runny Nose</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tiredness/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Trouble Sleeping</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John W. Newcomer</name_or_title>
      <organization>Florida Atlantic University</organization>
      <phone>(561) 297-0252</phone>
      <email>jnewcomer@health.fau.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

